Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.
Ninjacof chlophedianol hcl and pyrilamine maleate 12.5 mg/5mL; 12.5 mg/5mL Solution, 473 mL — NDC 23359-032-16 (Billing 23359-0032-16)
by Centurion Labs, LLC · 473 mL in 1 BOTTLE
This is a package of 473 mL of Ninjacof chlophedianol hcl and pyrilamine maleate 12.5 mg/5mL; 12.5 mg/5mL Solution from Centurion Labs, LLC, marketed since Oct 2014 and currently FDA-listed; retail pharmacies pay about $0.0792 per mL (NADAC). It is the main listing for this product, which comes in 3 package sizes.
NDC 23359-0032-16
🏷️ FDA NDC (as labeled)23359-032-16billing pads the product segment with a zero
This package
Contains473 mLCost per mL$0.0792 NADACPer package$37.46 / 473 ml Pack sizes3 compare ↓
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification
GPI-1443995702450930
GPI classNinjacof
GCN Seq No072924
GCN37227
HICL code040404
Ingredient (HICL)Pyrilamine/Chlophedianol
HIC1 codeB
Therapeutic class — broad (HIC1)Respiratory System
HIC2 codeB4
Therapeutic class — intermediate (HIC2)Drugs Affecting The Trachea And Bronchi (Contin.1)
HIC3 codeB4E
Therapeutic class — specific (HIC3)Non-Opioid Antitussive-1St Gen Antihistamine Comb.
AHFS code04:04.08.00
AHFS classEthylenediamine Derivatives
FDB label nameNINJACOF LIQUID
FDB brand nameNinjacof
Legend statusO — Over-the-counter (OTC) drug or device
Quick answers
GSN (GCN sequence number):072924
GCN:37227
GPI-14 (Medi-Span):43995702450930
HICL (First Databank):040404
AHFS class code:04:04.08.00
RxCUI (RxNorm):1593749
Why two NDCs?
The FDA registers this code as 23359-032-16 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 23359-0032-16. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.
This medicine belongs to the Other cough suppressants class.
Drug family (ATC)Other cough suppressants
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.
Label name NINJACOF LIQUIDIngredient Pyrilamine/Chlophedianol
🧪 What is this product?
Ninjacof is an over-the-counter oral liquid containing chlophedianol hydrochloride and pyrilamine maleate. Chlophedianol is a cough suppressant typically used to reduce coughing, while pyrilamine maleate is an antihistamine commonly used to help relieve symptoms associated with allergies and colds. This product is marketed as an OTC monograph drug, meaning it follows established FDA guidelines for its drug category rather than undergoing individual review.
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
Price system
Per mL
Per package
Retail pharmacies payNADAC · weekly
$0.079
$37.46 / 473 ml
Medicaid paysCMS SDUD · 12 mo
$0.0992
$46.92 / 473 ml
Medicare drug plans payPart D · quarterly
No Part D plan price is available for this NDC in our data.
NADAC price history (per mL) — tap or hover for the price & month
Flat over the last 4 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.
You're viewing the largest of 3 pack sizes for this product.
Pack size FAQ
What quantity is in this package?
This package contains 473 mL — 473 ml in 1 bottle.
How does this package differ from NDC 23359-0032-10?
Both are Ninjacof chlophedianol hcl and pyrilamine maleate 12.5 mg/5mL; 12.5 mg/5mL Solution — the drug itself is identical. This page's package is the 473 mL one, while NDC 23359-0032-10 is the 10 ml package.
What NDC number is used to bill for this package of Ninjacof chlophedianol hcl and pyrilamine maleate 12.5 mg/5mL; 12.5 mg/5mL Solution?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.
Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.
We did not find an FDA-approved generic match for this exact strength, form and route.
Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.
Inactive ingredients, also called excipients, are components of the drug product
other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors,
or other formulation ingredients.
Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.
Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.
Manufacturer & labeler
LabelerCenturion Labs, LLC
FDA applicationM012 (OTC MONOGRAPH DRUG)
Labeler code23359
First marketedOct 2014
Product typeHuman Otc Drug
Portfolio2 products on file
More NDCs from Centurion Labs, LLC labeler code 23359
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.
The complete FDA label for this product — the official Drug Facts labeling, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
INDICATIONS & USAGE SECTION Uses Temporarily relieves these symptoms due to the common cold, hay fever (allergic rhinitis) or other upper respiratory allergies: cough due to minor throat and bronchial irritation calms the cough control center and relieves coughing runny nose sneezing itching of the nose and throat itchy, watery eyes
⏱️Dosage and Administration111 words▾
Dosage and Administration Directions Do not exceed recommended dosage. Use calibrated measuring device for administering the drug to a child. Adults and children 12 years of age and over: 2 teaspoonfuls (10 ml) every 6 to 8 hours, not to exceed 6 teaspoonfuls in 24 hours, or as directed by a doctor.
Children 6 to under 12 years of age: 1 teaspoonful (5 ml) every 6 to 8 hours, not to exceed 3 teaspoonfuls in 24 hours, or as directed by a doctor. Children under 6 years of age: Consult a doctor. Other Information Store at 20° -25°C (68°-77°F); excursions permitted to 15°-30°C (59° - 86°F). [See USP Controlled Room Temperature].
⚠️Warnings145 words▾
WARNINGS SECTION WARNINGS Do not exceed recommended dosage DO NOT USE IF PRINTED SAFETY SEAL IS MISSING OR BROKEN If you are now taking prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression, psychiatric, or emotional conditions or Parkinsons disease), or for 2 weeks after stopping the MAOI drug. If you do not know if your prescription drug contains an MAOI, ask a doctor or pharmacist before taking this product. Ask a doctor before use if you have A cough that lasts or is chronic such as occurs with smoking, asthma, or emphysema A cough that occurs with too much phlegm (mucus) Ask a doctor or pharmacist before us if you are: Taking sedatives or tranquilizers If you have a breathing problem such as emphysema or chronic bronchitis If you have glaucoma If you have difficult in urination due to enlargement of the prostate gland
🧪Active Ingredient24 words▾
OTC - ACTIVE INGREDIENT SECTION Active ingredients (in each 5 ml) Purpose Chlophedianol HCI 12.5 mg ..................................... Antitussive Pyrilamine Maleate 12.5 mg ................................. Antihistamine
OTC - DO NOT USE SECTION Stop use and ask a doctor if Nervousness, dizziness, or sleeplessness occurs Symptoms do not improve within 7 days or are accompanied by a fever, rash, or persistent headache. A persistent cough may be a sign of a serious condition. New symptoms occur
📄When Using This Product41 words▾
OTC - WHEN USING SECTION When using this product Excitability may occur, especially in children Marked drowsiness may occur Avoid alcoholic drinks Alcohol, sedatives, and tranquilizers may increase the drowsiness effect Be careful when driving a motor vehicle or operating machinery
🤰If Pregnant or Breast-Feeding17 words▾
OTC - PREGNANCY OR BREAST FEEDING SECTION If pregnant or breast-feeding Ask a health professional before use.
📄Keep Out of Reach of Children29 words▾
OTC - KEEP OUT OF REACH OF CHILDREN SECTION Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center immediately.
📄Questions or Comments18 words▾
OTC - QUESTIONS SECTION Questions? Comments? To report a serious adverse event or obtain product information, contact 1-866-959-4880
📄Package Label / Principal Display Panel128 words▾
No label section mentions that — try another word, or open the full label on DailyMed below.
Glossary — plain-language definitions of medical terms used in this label:
Active ingredient: The part of a medicine that produces its intended effect on the body.
adverse event: Any unwanted medical problem that happens during treatment, whether or not the medicine actually caused it.
depression: A lasting low mood with loss of interest that affects everyday life.
Dosage and Administration: The label section explaining how much of a medicine to use and how to take or give it.
glaucoma: An eye condition, often linked to high pressure inside the eye, that can slowly damage vision.
Inactive ingredient: A component of a medicine, such as a filler, binder, or dye, that does not produce the intended effect.
inhibitor: A substance that blocks an enzyme or transporter, which can raise the levels of drugs it normally handles.
serious adverse event: A harmful event during treatment that is life-threatening, requires hospital care, or causes lasting harm.
Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA.
Prefer the government’s original formatting? View this label on DailyMed ↗
Medicaid utilization & spend
📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
29
Units reimbursed last 4 qtrs
3.7K
Gross reimbursed last 4 qtrs
$367.30
Avg / prescription
$12.67
Avg / unit
$0.0992
Latest quarter Q1 2026
15Rx
Medicaid pays / mL
$0.0992
gross reimbursed
vs
NADAC / mL
$0.0792
acquisition cost
=
Spread
+$0.0200
+25% vs cost
What Medicaid paid per mL (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
100% MCO
Fee-for-service · 0 Rx Managed care · 29 Rx
State Medicaid map
Units reimbursed · per 100k residents
33.633.6
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
Prescriptions—
Units—
Reimbursed—
🏆 Top states by units · per 100k residents
1Georgia33.6 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.
Medicaid utilization by pack size
Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
Drug total (last 4 qtrs): 29 Rx · 3,701 units · $367 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.
Reported adverse events (FAERS)
Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Chlophedianol hcl and pyrilamine maleate — the ingredient across all brands.
Top reported reactions
Diarrhoea5
Rash4
Blister3
Influenza3
Nausea3
Pain3
Anxiety2
Age at onset
Adult8
Elderly3
Reporter sex
Male · 33%
Female · 67%
Serious outcomes
Hospitalization6
Reports over time (by year) — tap or hover for the count & year
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.
For educational and professional reference only — not medical advice. Pricing reflects published
NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.
